Over 10,000 women enrolled at over 1,000 sites

The largest randomised adjuvant breast cancer treatment trial ever conducted

TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.


Read the article on NEJM
 

TAILORX: TRANSFORMING THE TREATMENT OF BREAST CANCER

The TAILORx trial followed over 10,000 women with early breast cancer for an average of 9 years. Over 1,000 trial sites in 6 countries participated.

The Oncotype DX Breast Recurrence Score test is the only genomic test proven to predict a patient's individual benefit of chemotherapy.


Learn more about the test
REFERENCES

  1. Sparano et al. N Engl J Med. 2015.
  2. Sparano et al. N Engl J Med. 2018.

NIH = National Institute of Health

RS = Recurrence Score result

TAILORx = A Clinical Trial Assigning IndividuaLized Options for Treatment (Rx)

The TAILORx trial was conducted independently by the ECOG-ACRIN Cancer Research Group.

Contact Us

Get in Touch
Making cancer care smarter.™
X

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy.